<?xml version="1.0" encoding="UTF-8"?>
<p>Faced with a new disease, numbers of patients that have in many cases vastly overwhelmed healthcare resources, and no available effective treatment, an extraordinary array of experimental therapies have been given to critically ill patients, often in combination. Whether this approach has harmed more patients that it has helped remains to be seen. Desperate times are felt to justify desperate measures. However, in this issue of the 
 <italic>Journal</italic>, the case series by Du and colleagues (pp. 
 <ext-link ext-link-type="doi" xlink:href="10.1164/rccm.202003-0543OC" xmlns:xlink="http://www.w3.org/1999/xlink">1372â€“1379</ext-link>) (
 <xref rid="bib3" ref-type="bibr">3</xref>) demonstrates that access to basic critical care support, not experimental therapies, is the most important determinant of the high mortality reported in some SARS-CoV-2 series. Despite acute respiratory distress syndrome in 74% and shock in 81%, only 21% of cases received invasive mechanical ventilation.
</p>
